Behavioral Activation Intervention, Reward Processing, and Youth Smoking Cessation
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01351766|
Recruitment Status : Unknown
Verified June 2011 by University of Maryland, College Park.
Recruitment status was: Recruiting
First Posted : May 11, 2011
Last Update Posted : June 13, 2011
|Condition or disease||Intervention/treatment||Phase|
|Smoking||Drug: Transdermal Nicotine Patch||Phase 3|
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||30 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Official Title:||Behavioral Activation Intervention, Reward Processing, and Youth Smoking Cessation|
|Study Start Date :||April 2010|
|Estimated Primary Completion Date :||March 2013|
|Estimated Study Completion Date :||April 2013|
Experimental: Behavioral Activation Treatment for Smoking
BATSY includes standard smoking cessation strategies and identifying life areas, values, and daily activities to help manage mood. Participants will complete between group exercises and will also monitor and plan daily activities in line with their values. Treatment will be delivered in 8, 60-minute group sessions over an 8-week period.
Drug: Transdermal Nicotine Patch
8 weeks of the Transdermal Nicotine Patch Nicoderm CQ at 24 hour doses of 21, 14, and 7 mg respectively depending on participant's initial level of nicotine use. Nicotine patch dose will decrease at 2 or 4 week increments also specific to participant's initial nicotine level.
- Smoking abstinence based on expired carbon monoxide tests, urinary cotinine tests, and self report [ Time Frame: 12 months post quit date ]
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01351766
|Contact: Laura MacPherson, PhDemail@example.com|
|United States, Maryland|
|University of Maryland, College Park||Recruiting|
|College Park, Maryland, United States, 20742|
|Contact: Laura MacPherson, PhD 301-405-7895 firstname.lastname@example.org|
|Principal Investigator:||Laura MacPherson, PhD||University of Maryland, College Park|